AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment

Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment

Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment

Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer

Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor